Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/15/2021 10/18/2021 10/19/2021 10/20/2021 10/21/2021 Date
247.68(c) 261.09(c) 262.85(c) 269.42(c) 282.61 Last
1 654 029 2 011 888 3 854 495 2 029 221 1 721 634 Volume
-1.06% +5.41% +0.67% +2.50% +4.90% Change
More quotes
Estimated financial data (e)
Sales 2021 16 684 M 19 421 M 19 421 M
Net income 2021 8 759 M 10 196 M 10 196 M
Net cash position 2021 8 861 M 10 314 M 10 314 M
P/E ratio 2021 6,60x
Yield 2021 -
Sales 2022 17 092 M 19 896 M 19 896 M
Net income 2022 9 597 M 11 171 M 11 171 M
Net cash position 2022 19 762 M 23 004 M 23 004 M
P/E ratio 2022 6,24x
Yield 2022 -
Capitalization 55 841 M 65 071 M 65 000 M
EV / Sales 2021 2,82x
EV / Sales 2022 2,11x
Nbr of Employees 2 500
Free-Float 87,3%
More Financials
Company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer... 
More about the company
Ratings of BioNTech SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIONTECH SE
12:48pBIONTECH : Shares Rise After Data Shows Efficacy of COVID-19 Vaccine's Booster Dose
MT
11:29aGLOBAL MARKETS LIVE : Tesla, Unilever, Paypal, Elliott, Novartis...
11:26aCanada, Pfizer Strike Deal on Pediatric Vaccine Doses
DJ
11:07aEuropean ADRs Move Lower in Thursday Trading
MT
08:21aPFIZER : BioNTech Say Phase 3 Trial Data Showed Efficacy of Their COVID-19 Vaccine's Boost..
MT
07:14aBIONTECH : PFIZER ANDBIONTECH ANNOUNCE PHASE 3 TRIAL DATA SHOWING HIGH EFFICACY OF A COVID..
PU
07:07aPFIZER : BioNTech Report Nearly 96% Efficacy from COVID-19 Vaccine Booster Dose
MT
06:46aPRESS RELEASE : Pfizer and BioNTech Announce Phase -4-
DJ
06:46aPRESS RELEASE : Pfizer and BioNTech Announce Phase -3-
DJ
06:46aPRESS RELEASE : Pfizer and BioNTech Announce Phase -2-
DJ
06:46aPRESS RELEASE : Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a..
DJ
06:45aBIONTECH : Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Boos..
AQ
05:38aPFIZER : BioNTech's COVID-19 Vaccine Provides Strong Protection in Adolescents from Delta ..
MT
05:34aPFIZER, BIONTECH : Phase 3 Study Shows High Efficacy of Covid-19 Vaccine Booster
DJ
04:56aNovartis Signs New Deal With BioNTech to Support Production of Covid-19 Vaccine
MT
More news
News in other languages on BIONTECH SE
12:48pLes actions de BioNTech augmentent après que les données montrent l'efficacité de la do..
12:10pMÄRKTE USA/Leichte Gewinnmitnahmen - Tesla auf Rekordkurs
11:26aWHO setzt Prüfung von Sputnik-Impfstoff nach Unterbrechung fort
11:07aLes ADR européens en baisse jeudi
09:59aMÄRKTE USA/Wall Street mit leichten Gewinnmitnahmen
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Last Close Price 231,20 €
Average target price 257,72 €
Spread / Average Target 11,5%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE230.50%65 071
GILEAD SCIENCES, INC.14.76%83 830
WUXI APPTEC CO., LTD.25.14%64 894
REGENERON PHARMACEUTICALS16.48%58 504
VERTEX PHARMACEUTICALS-21.52%48 121
BEIGENE, LTD.44.20%34 774